Oneness Biotech Co Ltd
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, an innovative wound care medical device. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase II… Read more
Oneness Biotech Co Ltd (4743) - Total Assets
Latest total assets as of September 2025: NT$11.84 Billion TWD
Based on the latest financial reports, Oneness Biotech Co Ltd (4743) holds total assets worth NT$11.84 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oneness Biotech Co Ltd - Total Assets Trend (2009–2024)
This chart illustrates how Oneness Biotech Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oneness Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Oneness Biotech Co Ltd's total assets of NT$11.84 Billion consist of 53.4% current assets and 46.6% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 7.7% |
| Accounts Receivable | NT$18.34 Million | 0.1% |
| Inventory | NT$117.12 Million | 0.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$1.12 Billion | 8.2% |
| Goodwill | NT$57.44 Million | 0.4% |
Asset Composition Trend (2009–2024)
This chart illustrates how Oneness Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oneness Biotech Co Ltd's current assets represent 53.4% of total assets in 2024, a decrease from 76.3% in 2009.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2024, down from 60.9% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 8.2% of total assets.
Oneness Biotech Co Ltd Competitors by Total Assets
Key competitors of Oneness Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Oneness Biotech Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Oneness Biotech Co Ltd generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Oneness Biotech Co Ltd is currently not profitable relative to its asset base.
Oneness Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 37.04 | 39.99 | 58.15 |
| Quick Ratio | 36.38 | 39.33 | 57.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$6.05 Billion | NT$ 7.26 Billion | NT$ 8.78 Billion |
Oneness Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Oneness Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.66 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -11.1% |
| Total Assets | NT$13.66 Billion |
| Market Capitalization | $528.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oneness Biotech Co Ltd's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Oneness Biotech Co Ltd's assets decreased by 11.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oneness Biotech Co Ltd (2009–2024)
The table below shows the annual total assets of Oneness Biotech Co Ltd from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$13.66 Billion | -11.09% |
| 2023-12-31 | NT$15.36 Billion | -1.39% |
| 2022-12-31 | NT$15.58 Billion | -0.96% |
| 2021-12-31 | NT$15.73 Billion | +2.25% |
| 2020-12-31 | NT$15.38 Billion | +120.42% |
| 2019-12-31 | NT$6.98 Billion | +198.86% |
| 2018-12-31 | NT$2.34 Billion | -7.38% |
| 2017-12-31 | NT$2.52 Billion | -1.34% |
| 2016-12-31 | NT$2.56 Billion | -8.96% |
| 2015-12-31 | NT$2.81 Billion | +39.36% |
| 2014-12-31 | NT$2.01 Billion | -3.61% |
| 2013-12-31 | NT$2.09 Billion | +46.55% |
| 2012-12-31 | NT$1.43 Billion | +2.80% |
| 2011-12-31 | NT$1.39 Billion | +25.23% |
| 2010-12-31 | NT$1.11 Billion | -0.49% |
| 2009-12-31 | NT$1.11 Billion | -- |